Brigitte Laguerre
Overview
Explore the profile of Brigitte Laguerre including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
2735
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Duval L, Allignet B, Chevreau C, Gravis G, Mazza C, Gross-Goupil M, et al.
Clin Genitourin Cancer
. 2025 Mar;
23(2):102310.
PMID: 40037955
Introduction: Metastatic seminomatous germ cell tumors (mSGCT) are a rare form of cancer. Few studies focused on early relapse (<12 months) after first-line chemotherapy (ChT). We aimed to retrospectively evaluate...
2.
Houede N, Chevallier T, Audenet F, Thibault C, Neuzillet Y, Abraham C, et al.
J Clin Oncol
. 2025 Feb;
:JCO2500179.
PMID: 39951246
Purpose: After radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC), prognosis is poor for high-risk patients. This study evaluated safety and efficacy of neoadjuvant chemotherapy (cisplatin or carboplatin +...
3.
Fizazi K, Le Teuff G, Flechon A, Pagliaro L, Mardiak J, Geoffrois L, et al.
J Clin Oncol
. 2024 Aug;
42(28):3270-3276.
PMID: 39167741
JCO GETUG-13 established that switching patients with poor-prognosis nonseminomatous germ-cell tumors with an unfavorable marker decline to intensified chemotherapy resulted in improved outcomes. Here, we report the GETUG-13 long-term efficacy...
4.
Yu E, Ferrario C, Linch M, Stoeckle M, Laguerre B, Arranz J, et al.
Eur Urol Oncol
. 2024 Jun;
PMID: 38926066
Background And Objective: Abiraterone acetate (abiraterone) plus prednisone is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Our aim was to evaluate the efficacy and safety of pembrolizumab...
5.
Naffrichoux J, Poupin P, Pouillot W, Linassier C, Rioux-Leclercq N, De Vries-Brilland M, et al.
Eur J Cancer
. 2024 May;
205:114121.
PMID: 38749111
Introduction: Papillary renal cell carcinoma (pRCC) is a rare and aggressive cancer with no specifically established therapeutic strategy in the metastatic setting. Combinations of tyrosine kinase and immune checkpoint inhibitors...
6.
Carril-Ajuria L, Lavaud P, Dalban C, Negrier S, Gravis G, Motzer R, et al.
Eur J Cancer
. 2024 Apr;
204:114048.
PMID: 38653033
Background: The Lung Immune Prognostic Index (LIPI) is associated with immune checkpoint inhibitors (ICI) outcomes across different solid tumors, particularly in non-small cell lung cancer. Data regarding the prognostic and/or...
7.
Mourey L, Rainho L, Dalban C, Carril-Ajuria L, Negrier S, Chevreau C, et al.
Eur J Cancer
. 2024 Feb;
201:113589.
PMID: 38382153
Introduction: Immune checkpoint inhibitors are standard of care in metastatic renal cell carcinoma but their activity and safety in elderly patients is insufficiently explored. We evaluated outcomes of elderly patients...
8.
Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, et al.
Lancet Oncol
. 2023 Dec;
25(2):255-264.
PMID: 38142702
Background: The optimal perioperative chemotherapy for patients with muscle-invasive bladder cancer is not defined. The VESPER (French Genito-Urinary Tumor Group and French Association of Urology V05) trial reported improved 3-year...
9.
Yu E, Berry W, Gurney H, Retz M, Conter H, Laguerre B, et al.
Eur Urol Oncol
. 2023 Nov;
7(3):509-518.
PMID: 37940446
Background: Limited responses have been observed in patients treated with enzalutamide after disease progression on abiraterone for metastatic castration-resistant prostate cancer (mCRPC), but androgen receptor signaling impacts T-cell function. Objective:...
10.
Billon E, Dalban C, Oudard S, Chevreau C, Laguerre B, Barthelemy P, et al.
Eur Urol Oncol
. 2023 Oct;
7(4):742-750.
PMID: 37813745
Background: Glandular metastases (GMs; adrenal gland, pancreas, thyroid, ovary, breast, or prostate) are rare in metastatic clear cell renal cell carcinoma (mccRCC). Previous studies have indicated that GM patients treated...